Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy

Published:2018-05-08 Issue:1 Volume:150 Page:34-42
ISSN:0002-9173
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:

Author:

Landmann Alessandra¹,Farrugia Daniel J¹,Zhu Li²,Diego Emilia J¹,Johnson Ronald R¹,Soran Atilla¹,Dabbs David J³,Clark Beth Z³,Puhalla Shannon L⁴,Jankowitz Rachel C⁴,Brufsky Adam M⁴,Ahrendt Gretchen M¹,McAuliffe Priscilla F¹,Bhargava Rohit³

Affiliation:

1. Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA

2. Department of Biostatistics University of Pittsburgh, Pittsburgh, PA

3. Division of Breast and Gynecologic Pathology, Department of Pathology, Pittsburgh, PA

4. Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/ajcp/article-pdf/150/1/34/24973471/aqy028.pdf

Reference25 articles.

1. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer;Hammond;J Clin Oncol,2010

2. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer;Harvey;J Clin Oncol,1999

3. The role of primary endocrine therapy in older women with operable breast cancer;Johnston;Future Oncol,2015

4. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy;Morgan;Breast,2011

5. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer;Cuzick;J Clin Oncol,2011

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer;JNCI: Journal of the National Cancer Institute;2024-07-31

2. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients;Clinical Breast Cancer;2024-07

3. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center;The Breast;2024-06

4. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan;Breast Cancer;2024-04-29

5. Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis;The Oncologist;2024-04-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3